Components of Hib Vaccine	Excipients Table Allergens Table Components Table
Indication Induction of active immunity against invasive diseases caused by Haemophilus influenzae type b Proprietary Name PedvaxHIB ActHIB/OmniHIB Hiberix Manufacturers Merck sanofi pasteur/ GlaxoSmithKline GlaxoSmithKline Viability Inactivated Inactivated Inactivated Microorganism H. influenza Neisseria meningitidis H. influenza (tetanus toxoid conjugate) Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate) Clostridium tetani Dose 0.5 mL 0.5 mL 0.5 mL Route Intramuscular Intramuscular Intramuscular Dosage form Suspension Powder for solution Sterile, Lyophilized powder Appearance Slightly opaque white Clear, Colorless after mixing Clear, Colorless after reconstitution Concentration (per 0.5 mL) Haemophilus b PRP, 7.5 mcg Polysaccharide, 10 mcg Hib Polysaccharide, 10 mcg Preservatives None None None Adjuvant Neisseria meningitides OMPC, 125 mcg Aluminum hydrosyphosphate sulfate, 225 mcg Sodium chloride, 0.9% Tetanus toxoid, 24 mcg Tetanus toxoid, 25 mcg Excipients None 8.5% sucrose, Ammonium sulfate Formalin Lactose, 12.6 mg Formaldehyde, Residual ≤0.05mcg Allergens None None None Media Complex fermentation Semisynthetic medium Synthetic medium Packaging Box of 10 single-dose vials Box of 5 single dose vials packaged with diluent Pakcage of 10 Single-dose vials Routine Storage 2 to 8° C (36-46° F) Do Not Freeze 2 to 8° C (36-46° F) Do Not Freeze 2 to 8° C (36-46° F) Protect from light Do Not Freeze updated May 2010
This page was last updated on October 03, 2011 © 2010 Institute for Vaccine Safety